Navigation Links
Omeros' Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
Date:11/5/2012

SEATTLE, Nov. 5, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today reported positive data from the second of its two pivotal Phase 3 clinical trials evaluating OMS302 in patients undergoing intraocular lens replacement surgery.  In this second Phase 3 clinical trial comparing OMS302 to placebo, OMS302 met its co-primary endpoints by demonstrating statistically significant (p<0.00001) maintenance of intraoperative mydriasis (pupil dilation) and statistically significant (p=0.0002) reduction of pain in the early postoperative period. OMS302, added to standard irrigation solution used during ophthalmological procedures, is Omeros' proprietary PharmacoSurgery™ product designed to maintain intraoperative mydriasis and reduce postoperative pain and irritation resulting from cataract and other lens replacement surgery. Now with positive data from both trials in the OMS302 Phase 3 clinical program, Omeros plans to submit a New Drug Application (NDA) with the U.S. Food and Drug Administration in the first half of 2013 and a Marketing Authorization Application (MAA) with the European Medicines Agency in mid-2013, potentially allowing sales in 2014.

This multicenter, double-blind, Phase 3 clinical trial enrolled 416 patients randomized 1:1 to receive either OMS302 or placebo. The co-primary endpoints were maintenance of intraoperative mydriasis (pupil dilation) and reduction of pain in the early postoperative period.  Mydriasis is critical to the safety and surgical ease of lens replacement surgery as intraoperative pupil constriction increases the risk of injury to intraocular structures and can substantially prolong surgical time.  OMS302 also achieved statistical significance in other clinically relevant measures. The results from this trial are consistent with those from Omeros' first OMS302 Phase 3 and earlier Phase 2b clinical trials.

'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Omeros to Present at Deutsche Bank Securities Health Care Conference
2. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Announces Proposed Public Offering of Common Stock
5. Omeros Prices $30 Million Public Offering of Common Stock
6. Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
7. Omeros Successfully Completes Preclinical Studies of OMS824 for Schizophrenia and Phase 1 Clinical Trial Preparations Underway
8. Omeros Announces Discovery in MASP-2 Program
9. Omeros Corporation Reports Second Quarter 2012 Financial Results
10. Omeros Announces Completion of Enrollment in OMS103HP Phase 3 Clinical Trial
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Quebec , Jan. 15, 2014  Valeant Pharmaceuticals International, ... announced that the applicable waiting period under the Hart-Scott-Rodino ... the previously announced tender offer by its indirect wholly-owned ... outstanding shares of common stock of Solta Medical, Inc. ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s new ... targeting guide with accompanying instrumentation to place and insert ... to the soft tissue (e.g. ligament) repair or reconstruction ... repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3
... Pfizer Inc. (NYSE: PFE ) today announced ... Read, 57, currently head of the Company,s global biopharmaceutical ... Read succeeds Jeffrey B. Kindler, who has retired from ... The Board,s Lead Independent Director, Constance J. Horner, said, ...
... Dec. 3, 2010 Opto Circuits (India) Ltd. [BSE ... completed the merger of its wholly-owned subsidiary, Jolt Acquisition ... result of the transaction, Cardiac Science has become a ... follows (i) Opto Circuits, acquisition, through a tender offer ...
Cached Medicine Technology:Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 2Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 3Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 4Opto Circuits Successfully Completes Acquisition of Cardiac Science 2Opto Circuits Successfully Completes Acquisition of Cardiac Science 3
(Date:4/17/2014)... School of Medicine report that older women, plucky individuals ... are more likely to be compassionate toward strangers than ... this month,s issue of the International Journal of ... with better health and well-being as we age, the ... outcomes of individuals whose deficits in compassion put them ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... 2014) The cause of neuronal death in Parkinson,s ... that neurons may be mistaken for foreign invaders and ... the way autoimmune diseases like type I diabetes, celiac ... study was published April 16, 2014, in Nature ... controversial, idea in Parkinson,s disease; but if true, it ...
(Date:4/17/2014)... April 17, 2014 EcoHealth Alliance, a nonprofit organization ... published a comprehensive review today examining the current state ... The review calls for improved global surveillance strategies to ... recent outbreak of Ebola in West Africa that has ... of Guinea and Liberia. According to the World ...
(Date:4/17/2014)... NEW YORK (17 April 2014) Population Council scientists and ... is safe, stable, and can prevent the transmission of ... and rectum in animals: HIV, herpes simplex virus 2 ... provides the first data that the gel is effective ... of efficacy in the vagina against all three viruses ...
Breaking Medicine News(10 mins):Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... published in volume 14 issue 6 of World ... presented to Dr Cosimo Sperti of University of ... laparotomy performed in another hospital for an unresectable ... vein. Total pancreatectomy together with resection and reconstruction ...
... Ph.D., MBA, RN is vice president of research,and ... announced it,has appointed Joann Genovich-Richards, Ph.D., MBA, RN, ... research and measurement. The,position will support the development ... analyze existing data from accredited companies and,other sources ...
... March 13 inVentiv Clinical,Solutions, LLC (inVentiv Clinical), ... that they will establish operations in Latin,America, a ... will be,based in Sao Paulo, Brazil, with the ... inVentiv Clinical,s Latin American operations,will be led by ...
... TOC ; TSX: TOC) has been selected by ... care hospitals in high-growth urban and,suburban markets, to complete ... care hospitals., Like other health systems in the ... a limited field of candidates.,Thomson Healthcare, using its Market ...
... Ohio, March 13 Cardinal Health, a,global ... the safety and,productivity of health care, today ... Kaufmann as group president of its Healthcare ... role, Kaufmann, 45, will be responsible for ...
... the Future, JACKSON, Miss., March 13 ... technology partner, announces Christwood Retirement,Community in Covington, ... Study,(OBS) partner site for SamarionSolution(SM), the nursing ... Christwood, which recently celebrated a decade as ...
Cached Medicine News:Health News:URAC Announces New Leadership to Mine Health Care Management Data and Develop Measurement Programs 2Health News:URAC Announces New Leadership to Mine Health Care Management Data and Develop Measurement Programs 3Health News:inVentiv Clinical Expands Operations to Emerging Latin American Region 2Health News:inVentiv Clinical Expands Operations to Emerging Latin American Region 3Health News:Thomson Healthcare Undertakes Medical Staff Development Project for IASIS Healthcare 2Health News:Thomson Healthcare Undertakes Medical Staff Development Project for IASIS Healthcare 3Health News:Cardinal Health Names Michael C. Kaufmann to Lead Pharmaceutical Segment 2Health News:Samarion(SM) Announces Second Outcome Based Study Partner Site for LTC Industry's Only Enterprise Quality Improvement System 2Health News:Samarion(SM) Announces Second Outcome Based Study Partner Site for LTC Industry's Only Enterprise Quality Improvement System 3
Reagent Basin, 60mL, 5/Box...
Reservoir, 8 Well, 10/Box...
... manually adjustable dispensing head, and disposable, pre-sterilized ... cost-efficiency to microplate fluid dispensing. It is ... offer fast dispensing of fluids in a ... It also offers the added benefit of ...
The WellPro 384 is designed for use with 384 well microplates. It utilizes a 24 channel liquid head and can perform serial dilutions in a 16 or 24 across format, and plate to plate transfers and plat...
Medicine Products: